Moneycontrol PRO

Outskill Genai

HomeNewsBusinessMoneycontrol ResearchGland Pharma’s new product play for FY22 holds a lot of promise

Gland Pharma’s new product play for FY22 holds a lot of promise

While the US market is still expected to clock 18-20 per cent growth for Gland Pharma in FY22, the company’s foray into non-US markets would accelerate growth in the medium term

Anubhav Sahu

July 22, 2021 / 19:11 IST

Gland Pharma’s new product play for FY22 holds a lot of promise

Gland Pharma Limited | The share price has surged 124 percent to 3,367.05 on July 1, 2021, from its issue price of Rs 1,500. It was listed on exchanges on November 20, 2020, with an issue size of Rs 6,480 crore.

Watch Webinar

PRO Panorama

Moneycontrol Pro Panorama | Is India an AI hedge trade?

Nov 10, 2025 / 02:56 PM IST

In November 10 edition of Moneycontrol Pro Panorama: RBI opens M&A loan gate are Indian banks ready, extended US shutdown clouds m...
Read Now
PRO Weekender

Moneycontrol Pro Weekender | Samvat 2082: The Will to Rise

Oct 18, 2025 / 10:00 AM IST

After a turbulent Samvat 2081, the markets step into the new year not with fireworks but with quiet resolve and the will to rise
Read Now

Unlock This Article

Are you a PRO subscriber? Sign In

What Do You Get

Ad free Experience

Seamless navigation, faster responses.
Expert Perspective

Explore 230+ exclusive editorials every month
+

Uncover Insights from World-Renowned Experts and Journalists
Actionable Insights

40+ weekly investment ideas + 3 to 4 daily technical calls
Virtual Events

Exclusive Live Webinars for Expert Trading & Investment Strategies!
Newsletters

Stay ahead with daily and weekly insights

Unlock exclusive discounts

Disclosure & Disclaimer

This Research Report / Research Recommendation has been published by Moneycontrol Dot Com India Limited (hereinafter referred to as “MCD”) which is a registered Investment Advisor under the Securities and Exchange Board of India (Investment Advisers) ...Read More